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Objectives We sought to describe the diagnostic work-up, phenotype, and long-term evolution of dilated cardiomyopathy
(DCM) associated with Dystrophin (DYS) defects.
Background X-linked DCM associated with DYS defects can be clinically indistinguishable from other types of DCM.
Methods The series comprises 436 consecutive male patients diagnosed with DCM. Patients underwent endomyocardial
biopsy (EMB). Genetic testing employed multiplex polymerase chain reaction and multiple ligation dependent
probe assay for deletions and direct sequencing of the 79 exons and flanking regions of the gene for point muta-
tions or small rearrangements.
Results We identified DYS defects in 34 of 436 patients (7.8%) (onset age 34  11 years, age range 17 to 54 years); 30 had
proven X-linked inheritance. The 2 phenotypes included DCM with mild skeletal myopathy and/or increased serum
creatine phosphokinase (n  28) or DCM only (n  6). The EMB showed defective dystrophin immunostain. The DYS
defects consisted of 21 in-frame deletions and 11 out-of-frame deletions as well as 1 stop and 1 splice-site mutation.
During a median follow-up of 60 months (interquartile range: 11.25 to 101.34 months) we observed 17 events, all
related to heart failure (HF) (median event-free survival: 83.5 months). Eight patients (23%) underwent transplanta-
tion, and 9 (26%) died of HF while waiting for transplantation. Eight patients received an implantable cardioverter-
defibrillator, although none had device intervention during a median follow-up of 14 months (interquartile range: 5 to
25 months). No patient died suddenly, suffered syncope, or developed life-threatening ventricular arrhythmias.
Conclusions DYS-related DCM should be suspected in male patients with increased serum creatine phosphokinase (82%)
and X-linked inheritance. The disease shows a high risk of end-stage HF but a lower risk of life-threatening
arrhythmias. (J Am Coll Cardiol 2011;58:925–34) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.072Dystrophin (DYS) (MIM*300377, Xp21.2) defects cause
Duchenne Muscle Dystrophy (DMD), a severe myopathy
affecting children and adolescents; Becker Muscle Dystro-
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2010, accepted January 3, 2011.phy (BMD), a milder, delayed-onset myopathy with or
without cardiac involvement; and an X-linked dilated car-
diomyopathy (DCM) (MIM#302045) (1–12). DYS defects
presenting with isolated or predominant cardiac involve-
ment might be clinically indistinguishable from other types
of idiopathic DCM, especially when the myopathy is
subclinical, serum creatine phosphokinase (sCPK) is normal
or mildly elevated, or the family is small and masks an
X-linked recessive inheritance. DYS-related etiology can be
suspected in male patients with DCM, increased sCPK, and
absence of male-to-male transmission of the disease in the
family. Genetic testing and endomyocardial biopsy (EMB)
play a diagnostic role.
Most DYS defects causing DCM are deletions and cluster
in 2 different regions of the gene: the 5’ including muscle
promoter-exon 1 and hinge region (3,5–7,9) and mid-rod
domain exons (8,13,14). Prior comprehensive mutation
aM
F
4
i
i
f
D
m
p
i
d
c
e
e
r
o
c
n
fi
W
r
a
i
o
m
“
i
a
c
m
g
i
i
m
E
G
r
l
p
r
e
6
(
L
t
s
a
M
m
d
w
i
fi
r
s
w
t
s
p
c
3
E
t
t
m
t
c
S
d
p
s
t
r
h
926 Diegoli et al. JACC Vol. 58, No. 9, 2011
Dilated Cardiodystrophinopathies August 23, 2011:925–34scanning of the exons and splice
junctions of DYS in patients with
sporadic DCM without clinical
evidence of skeletal myopathy
identified putative point muta-
tions in 3 of 22 male patients
(13.6%) (15). In X-linked DCM,
the pattern of expression of DYS
mutations in cardiac muscle dif-
fers from that observed in skele-
tal muscle, suggesting relevant
differences of gene processing as
well as differences in the functional
domains more relevant for one tis-
sue versus the other (review in
Cohen and Muntoni [16]).
Most data on the natural his-
tory of X-linked DCM associ-
ated with DYS defects come from
the myology setting, namely
from patients who presented to
clinical attention because of my-
opathy. Left ventricular (LV) di-
lation and reduced left ventricu-
lar ejection fraction (LVEF)
occur in less than one-third of
the patients diagnosed with
BMD (14,17), and data on the
arrhythmogenic risk of X-linked
DCM are limited. The present
study sought to describe the
prevalence, diagnostic work-up,
phenotype, and long-term evolu-
tion of X-linked DCM associ-
ted with DYS defects.
ethods
rom January 1995 to December 2009, we screened DYS in
36 unrelated male probands diagnosed with DCM. The
nclusion criteria were male sex and DCM diagnosis accord-
ng to World Health Organization criteria (18). Because the
emale carriers of DYS defects might develop late-onset
CM, we only excluded probands from families with
ale-to-male transmission. The diagnostic work-up in
robands consisted of clinical examination, biochemical
nvestigation (total sCPK, sCPK cardiac isoform [myocar-
ial band], lactacidemia, and lactic dehydrogenase), electro-
ardiography, chest x-ray, 2-dimensional and Doppler
chocardiography, 24-h Holter recording, right heart cath-
terization, coronary angiography (after the age of 30 years),
ight ventricular EMB, and search for viral genomes (Meth-
ds in Online Appendix). Neuromuscular assessment fo-
used on detailed clinical history, physical examination, and
euromyological examination. Skeletal myopathy was de-
Abbreviations
and Acronyms
BMD  Becker Muscle
Dystrophy
CHF  congestive heart
failure
CI  confidence interval
DCM  dilated
cardiomyopathy
DMD  Duchenne Muscle
Dystrophy
DNA  deoxyribonucleic
acid
DYS  Dystrophin gene
EMB  endomyocardial
biopsy
HF  heart failure
HTx  heart
transplantation
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
LVEF  left ventricular
ejection fraction
MLPA  Multiple Ligation-
Dependent Probe
Amplification
NSVT  nonsustained
ventricular tachycardia
PCR  polymerase chain
reaction
sCPK  serum creatine
phosphokinasened by increase in serum CPK and/or muscle weakness. then possible, we traced the clinical and pathological
ecords and autopsy samples of deceased relatives. Informed
nd consenting family members underwent clinical screen-
ng, genetic counseling, and testing (19). The carrier status
f the parents and maternal relatives was assessed with
icrosatellite analysis (12). The disease was defined as
proven familial,” when clinical screening and genetic test-
ng documented a mutated mother, a mutated maternal
unt or uncle, maternal female carriers, and affected male
ousins; the family history was specified as “unknown” when
others or maternal relatives could not undergo clinical and
enetic screening. Additional data on families are available
n the Online Appendix. The clinical and research work-up
s part of a broader program dedicated to familial cardio-
yopathies and has been approved by the Institutional
thical Committee.
enetic testing. Genetic testing was performed in deoxy-
ibonucleic acid (DNA) isolated from peripheral blood
eukocytes. Until 2006, analysis of the DYS gene was
erformed with multiplex and single polymerase chain
eaction (PCR) assays (including the muscle promoter and
xons 2 to 8, 12, 13, 16, 17, 19, 29, 32, 34, 41 to 55, 58, 60,
1, 64, 66, 68 to 70, and 76), as previously described (19)
Online Fig. 1a). Since 2007, we have introduced Multiple
igation-Dependent Probe Amplification (MLPA) analysis
hat allows the simultaneous hybridization and ligation of
everal probes in a single reaction tube, followed by PCR
mplification and analysis by capillary electrophoresis. The
LPA analysis was carried out according to the recom-
endations of the manufacturer (MRC Holland, Amster-
am, the Netherlands) (20). The MLPA data were analyzed
ith GeneScan 3.7 software (Online Fig. 1b). All deletions
dentified in multiplex PCR assays and MLPA were con-
rmed with single exon PCR. The 79 coding and flanking
egions of the gene were analyzed by direct, bidirectional
equencing in the DNA of patients who tested negative
ith MLPA and showed abnormal DYS immunostain of
he myocytes in the EMB (Online Fig. 1c). Genomic
equences were derived from the Leiden Muscular Dystro-
hy Database. The MLPA analysis was performed in 118
ontrol DNA samples from non-affected male subjects (age
6  14 years, age range 18 to 55 years).
MB. Right ventricular EMB was performed in all pa-
ients as per standard protocol in a referral center for heart
ransplantation. The EMB samples were processed for light
icroscopy and ultrastructural study (12). The immunohis-
ochemical study was performed with antidystrophin mono-
lonal antibody at a dilution of 1:50, pH 9.9 (Monosan,
anbio B.V., Uden, the Netherlands, Clone Dy4/6D3, Rod
omain) according to the standard avidin– biotin–
eroxidase complex method. The immunohistochemical
tudy on paraffin sections was informative, independent of
he type of mutation, and substituted, in the first-level
outine diagnostic activity, for the more complex immuno-
istochemical stains with anti–C-terminus, anti–N-
erminus, and anti–Rod-domain antibodies on frozen sec-
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August 23, 2011:925–34 Dilated Cardiodystrophinopathiestions (12). We used, as control subjects, 22 EMBs from
donor hearts obtained before transplantation (HTx) and
EMBs from DCM patients with a negative genetic test for
DYS.
Statistical analysis. Descriptive statistics were computed as
mean  SD or median (25th to 75th percentiles) for
ontinuous variables and as absolute frequency and percent-
ge for categorical variables. For the purpose of analysis, age
t diagnosis was dichotomized at its median value. Event
ates (death plus HTx)/100 person-year and 95% confi-
ence intervals (CIs) were calculated. Kaplan-Meier
ethod was used to compute cumulative event-free survival.
vent-free survival curves of a series of potential predictors
ere compared by means of the log-rank test. No multi-
ariable analysis could be performed, given the limited
umber of events. To better characterize the occurrence
ver time of cardiac death or heart transplant in these
atients, we further described these events with the frame-
ork of competing risks; for this purpose we computed and
lotted the cumulative incidence (at the end of the follow-
p) for each of these competing events (21). Stata software
version 10.1, StataCorp, College Station, Texas) was used
or computation. A 2-sided p value  0.05 was considered
tatistically significant.
esults
tudy population and baseline characteristics. The in-
eritance was X-linked recessive in 30 of the 34 families
88%). Data from family and evaluation of living mothers
ere not available in 4 cases (12%). The clinical phenotype
as DCM with skeletal muscle involvement (either with
levated sCPK and muscle weakness [n  16] or increased
CPK only [n  12]) in 28 patients and solely DCM in 6
atients.
The mean age at clinical diagnosis of DCM was 34  11
ears, whereas the mean age at the diagnosis of DYS-related
CM was 35 12 years (range 17 to 54 years). Eight of the
4 patients (23%) had a documented episode of the flu,
hortly before the onset of DCM; these 8 patients were
linically diagnosed with myocarditis initially, but their
MB excluded inflammatory infiltrates. Quantitative PCR
xcluded the presence of viral genomes in the EMB samples
nd peripheral blood.
Electrocardiographic study showed nonspecific features
Table 1). Four (12%) patients had documented episodes of
onsustained ventricular tachycardia (NSVT) on Holter
onitoring (Table 1). None had syncope. Baseline echocar-
iographic study showed mean LV end-diastolic diameter
f 70 9 mm and LV end-diastolic volume of 279 83 ml
Table 1). The LVEF was 30  11%. Right ventricular
imensions (mean right ventricular diameter 25  2 mm)
nd function (mean tricuspid annular plane systolic excur-
ion 19  2) were preserved. The treatment included
eta-blockers, angiotensin-converting enzyme inhibitors,
ngiotensin II antagonists, furosemide, antialdosteronicgents, digoxin, amiodarone, anticoagulants or antiplatelets,
nd nitrates (Table 2).
enetic findings. We identified 32 deletions and 2 point
utations (Table 1). Of the 32 deletion defects, 11 were
ut-of-frame, whereas 21 were in-frame (Leiden Muscular
ystrophy pages—reading-frame checker version 1.9).
ost deletions involved the mid-rod domain region; dele-
ions exclusively affected regions spanning between exons 45
nd 55 in 28 of the 30 cases. Of the 2 point mutations, one
redicted a premature stop codon at p.Arg1763 (UMD-
710) and another one affected the splice site at –2 of intron
3 (Table 1). Healthy control subjects tested negative with
LPA; in particular, we did not find exon deletions in
ontrol subjects.
MBs. The control EMBs from both normal hearts of
onors before transplantation and DCM without DYS
efects showed homogeneous and intense sarcolemmal
mmunostain (Figs. 1 to 3). The EMBs from patients with
YS defects showed variable decreases of intensity of the
mmunostain and multifocal loss of dystrophin expression at
he myocyte membrane level involving entire or segments of
he sarcolemma, and as such, the immunostaining defects
ere either diffuse or patchy. The EMBs from the 3 patients
ith single deletion of exon 48 showed defective dystrophin
mmunostaining, as did EMBs of other patients with
ifferent mutations (Fig. 4).
utcome and prognostic stratification. Of the 34 affected
atients, 17 developed a major event over a median
ollow-up time of 82 months (interquartile range [IQR]: 29
o 125 months): 8 patients underwent HTx (mean LVEF
6%, range 10% to 20%) 23 months (IQR: 6 to 72 months)
fter diagnosis, and 9 died of congestive heart failure (CHF)
2 months (IQR: 15 to 81 months) after diagnosis while
waiting HTx. The mean age at the event was 41 13 years
(range 17 to 63 years); patients who underwent HTx were
younger (mean age at diagnosis 29.5 12 years, range 17 to
52 years) than those who died (mean age 42  10 years,
ange 19 to 55 years). Of the 8 HTx patients, 4 had pure
CM with no clinical signs of associated myopathy and
ormal sCPK values (66, 87, 76, and 176 mU/ml, respec-
ively), whereas 4 had increased sCPK (mean sCPK 601 
53 mU/ml, range 342 to 908 mU/ml). One of the 8
atients died of acute rejection 1 year after HTx: he had
efused immunosuppressant treatments, and clinical and
iopsy controls. Other HTx patients are alive and well.
ight patients received an implantable cardioverter-
efibrillator (ICD) (mean age 36  6 years, range 31 to 46
years); 1 underwent HTx 4 months later. The clinical
indications for ICD implantation were: severely decreased
LVEF and a single run of NSVT during an acute episode of
heart failure in 1 patient; decreased LVEF and 1 run of
NSVT recorded at Holter monitoring in a second patient;
and LVEF 30% in 6 patients. There were no appropriate
interventions of the devices during a median follow-up of 14
months from implantation (IQR: 5 to 25 months).
Baseline Demographic, Clinical, and Genetic DataTable 1 Baseline Demographic, Clinical, and Genetic Data
Case #
Age at 1st
Diagnosis (yrs) Family History Flu-Like Episode ECG
LVEF
(%)
LVEDD
(mm)
NYHA
Functional
Class NSVT ICD
sCPK mU/ml
(Normal Values <200) Events
Dystrophin Deleted
Exons and Point
Mutations
DystrophinIn- and
Out-of-Frame Del;
Other Mutations
1 17 1 0 ALVR 23 68 II 0 0 880 0 3–16 In-frame
2 27 NA 0 ALVR 20 69 III 0 1 850 0 45–49 In-frame
3 37 1 0 ALVR 28 76 II 0 0 813 CHF death 2–7 In-frame
4 43 2 0 Infer-Q-wave 30 65 II 0 0 850 0 45–47 In-frame
5 45 2 0 ALVR 40 68 II 0 0 850 0 45–47 In-frame
6 25 1 1 LBBB 15 67 III 0 0 66 HTx 48 In-frame
7 39 2 0 ALVR 40 64 II 0 0 657 CHF death 48 In-frame
8 27 2 0 ALVR 40 63 II 0 0 545 0 45, 47 Out-of-frame
9 17 1 0 ALVR 15 80 III 0 0 908 HTx 6, 8, 12, 13, 16,
17, 19, 44
Out-of-frame
10 30 2 0 PM 45 65 II 0 0 243 0 45, 47–48 Out-of-frame
11 29 2 0 ALVR 32 61 III 0 0 421 CHF death 45, 47 Out-of-frame
12 48 2 0 LBBB 23 76 III 1 0 672 CHF death 48–54 Out-of-frame
13 38 1 0 LBBB 30 75 III 1 1 367 CHF death 48 In-frame
14 23 1 1 LBBB  AVB,1st 20 83 IV 0 0 342 HTx 45–48 In-frame
15 24 2 0 ALVR 45 74 II 0 0 675 0 45–47 In-frame
16 54 2 0 LBBB 20 78 III 0 0 456 CHF death 48–55 In-frame
17 32 1 1 LBBB 24 77 III 0 0 87 HTx 3, 4, 6 Out-of-frame
18 52 2 0 ALVR 28 75 III 0 0 76 HTx 45–48 In-frame
19 49 NA 0 LBBB AVB,1st 23 80 III 0 0 121 CHF death 45–52 Out-of-frame
20 26 1 1 Infer-Q-wave 39 64 I 1 1 2,772 0 48–49 In-frame
21 40 1 0 ALVR 50 62 I 0 0 601 0 45–54 Out-of-frame
22 21 1 0 ALVR 50 52 I 0 0 765 0 p.(Arg1763X)* Nonsense
23 24 NA 0 ALVR 30 59 II 0 0 890 0 45–46 In-frame
24 29 1 0 LBBB 20 82 III 0 1 456 HTx 48–51 In-frame
25 17 1 1 Infer-Q-wave 22 73 IV 0 0 697 HTx 45–48 In-frame
26 19 1 1 LBBB 20 83 IV 0 1 112 CHF death 48–49 In-frame
27 19 1 0 ALVR 50 52 I 0 0 256 0 45–48 In-frame
28 42 NA 1 LBBB 20 78 III 0 0 176 HTx IVS13-2AT† Splice site†
29 44 1 0 Infer-Q-wave 35 57 II 1 0 955 0 45, 47–51 Out-of-frame
30 41 2 0 PM 25 71 II 0 0 501 CHF death 45, 47–48 Out-of-frame
31 35 1 0 ALVR 40 59 II 0 0 757 0 45–46 In-frame
32 44 1 0 LBBB 20 59 II 0 1 980 0 46–48 Out-of-frame
33 29 1 0 PM 30 78 II 0 1 3,370 0 45–55 In-frame
34 37 1 1 ALVR 15 82 III 0 1 620 0 45–47 In-frame
Family history: 1)  proven in mothers (n  17), or 2) maternal relatives (n  13). *(UMD-1710); †at IVS13-2, the c.1603-2AC is reported (UMD-1710) in Becker Muscle Dystrophy (BMD) associated with dilated cardiomyopathy (DCM) and cramps and weak dystrophin
immunostain; predicted p (Val535_Gln568del, Val535_Ala604Del).
ALVR  abnormal left ventricular repolarization; AVB,1st  first-degree atrioventricular block; CHF  congestive heart failure; Del  deletion; ECG  electrocardiogram; HTx  heart transplantation; ICD  implantable cardioverter-defibrillator; LBBB  left bundle branch
block; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction; NA  nonavailable deoxyribonucleic acid samples from mothers and other maternal relatives; NSVT  nonsustained ventricular tachycardia on Holter monitoring; NYHA  New
York Heart Association functional class; PM  pacemaker; sCPK  serum creatine phosphokinase.
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August 23, 2011:925–34 Dilated CardiodystrophinopathiesThe event rate for combined death and HTx was
9.1/100 person-year (95% CI: 5.7 to 14.7), with a median
event-free survival of 81 months, whereas the death rate was
4.8/100 person-year (95% CI: 2.51 to 9.3). The cumulative
event-free survival was 75% (95% CI: 56% to 86%) at 2
years and 64% (95% CI: 45% to 78%) at 5 years. Figure 5A
shows the Kaplan-Meier curve of the combined events
(death or HTx). At univariable analysis (Table 3), a lower
LVEF, larger LV end-diastolic diameter, higher New York
Heart Association functional class, normal sCPK, and
absence of myopathy were all associated with an increased
risk of events. With the analysis for competing risks, the
cumulative incidence of cardiac death (all end-stage heart
failure [HF]) and HTx at the end of follow-up were 36%
(95% CI: 18% to 54%) and 28% (95% CI: 13% to 45%),
respectively; the risk was substantially constant up to 96
months (as shown by the constant slope of the cumulative
incidence curve in Fig. 5B) and similar for both outcomes.
Additional data on families are available in the Online
Appendix.
Discussion
X-linked DCM associated with DYS gene defects consti-
tutes 10% of all DCM in a consecutive male series.
iagnosis. The contributory clinical markers for specific
diagnosis of DYS-related DCM were male sex, increased
Baseline Characteristics of the 34 DYS MutationC rriers According to Their Cardiologic Sta us,and Medical Treatment at Basel ne Diagnosisat End of Follow-Up
Table 2
Baseline Characteristics of the 34 DYS Mutation
Carriers According to Their Cardiologic Status,
and Medical Treatment at Baseline Diagnosis
and at End of Follow-Up
sCPK (mU/ml) 700 670 (66–3,370)
LVEF (%) 30 11 (15–50)
LVEDD (mm) 70 9 (52–83)
LVEDV (ml) 279 83 (136–475)
RV diameter (mm) 25 2 (22–31)
TAPSE (mm) 19 2 (17–26)
NYHA functional class
I 4 (12%)
II 14 (41%)
III 13 (38%)
IV 3 (9%)
III–IV 16/34 (47%)
Treatments Baseline End follow-up
Beta-blockers 9/34 (25%) 30/34 (88%)
ACE inhibitors 13/34 (38%) 30/34 (88%)
ATI antagonists 1/34 (3%) 7/34 (21%)
Furosemide 10/34 (29%) 27/34 (79%)
Digitalis 4/34 (12%) 15/34 (44%)
Antialdosteronic agents 7/34 (21%) 19/34 (56%)
Amiodarone 2/34 (6%) 5/34 (15%)
Anticoagulants/platelet antiaggregants 11/34 (32%) 29/34 (85%)
Nitrates 1/34 (3%) 3/34 (9%)
Values are mean  SD (range), n (%), or n/N (%).
ACE  angiotensin-converting enzyme; ATII  angiotensin II; LVEDV  left ventricular end-
diastolic volume; RV right ventricular; TAPSE tricuspidal annular plane systolic excursion; other
abbreviations as in Table 1.CPK and absence of male-to-male transmission of the diseasein the families. These markers recur in more than 80% of the
patients. The age of onset does not help, because the age at
diagnosis might go beyond 50 years (14,19). Another support-
ing clinical marker is the presence of deep Q waves in inferior
leads that has been previously described in DMD and BMD
(22). However, only 4 of our patients had these electrocardio-
graphic changes. The EMB plays a fundamental role docu-
menting the loss of dystrophin expression in the myocardium,
and genetic testing concludes the diagnostic work-up. Routine
cardiac magnetic resonance imaging would contribute to better
characterization of the distribution of fibrosis in the LV
inferolateral wall (23).
Figure 1 Out-of-Frame Deletions Versus Control: Defective
Immunohistochemical Expression of Dystrophin
(A) Control endomyocardial biopsy (EMB) showing regular and intense immuno-
stain of the sarcolemma; (B) EMB performed at the time of diagnosis in
Patient #9 and (C) Patient #12 (Table 1), both carriers of different out-of-frame
deletions, showing severe decrease of the dystrophin immunostain and cardio-
myopathic changes (more prominent in the heart of Patient #9).
930 Diegoli et al. JACC Vol. 58, No. 9, 2011
Dilated Cardiodystrophinopathies August 23, 2011:925–34The history of a recent flu episode, observed in 8 of our
patients, might mislead the clinical diagnosis. However, the
possibility of a viral flu triggering the onset of a pre-existing
asymptomatic disease or initiating clinical investigation of
cardiovascular disease cannot be excluded. One of the 4
Figure 2 In-Frame and Splice Site Mutations: Defective
Immunohistochemical Expression of Dystrophin
(A) Control dilated cardiomyopathy showing regular and intense immunostain
of the sarcolemma; (B) endomyocardial biopsy (EMB), Patient #24 (Table 1),
carrier of an in-frame deletion; and (C) Patient #28, carrier of a splice site
mutation. The loss of protein expression associated with in-frame deletions
was variable, with groups of myocytes maintaining intense immunostain and
large areas of myocardium showing loss of protein expression. The dystrophin
expression associated with the splice site mutation was characterized by low
intensity and extensive loss of the immunostain.X-linked DCM cases reported by Neri et al. (24) hadsudden cardiac failure after a flu-like illness. Although
myocarditis and viral genome were absent in the EMB of
our patients, we cannot exclude that the myocardium with
DYS defects is more exposed to the damage induced by
coxsackievirus proteases that can affect host cell proteins
such as dystrophin (25).
Genetic tests should be performed—on the basis of
Figure 3 In-Frame and Out-of-Frame Deletions: Defective
Immunohistochemical Expression of Dystrophin
(A) Control dilated cardiomyopathy showing regular and intense immunostain
of the sarcolemma; (B, C) extensive loss of dystrophin in the endomyocardial
biopsies (EMBs) from Patient #25, carrier of the in-frame deletion of exons 45
to 48 (B) and Patient #11, carrier of the out-of-frame deletion of exons 45 and
47 (C). The comparative view of the dystrophin immunostain documents that
the loss of protein expression can be severe and similar in the myocardium of
patients with in-frame and out-of-frame deletions.present data that are the results of comprehensive immu-
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August 23, 2011:925–34 Dilated Cardiodystrophinopathiesnohistochemical and genetic screening in male patients—in
all patients with EMB showing defective DYS immuno-
taining. In fact, the results demonstrate that the loss of
ystrophin expression in the affected myocardium is specific
nd sufficient to perform first-level DYS testing with
LPA. Direct sequencing of the coding and flanking
egions of the gene should be performed when the EMB
hows defective dystrophin immunostaining and MLPA is
egative. The MLPA carries a high probability of detection
f the genetic defect, because more than 90% of our patients
ith X-linked DCM showed deletions. The advantage of
LPA with respect to the previously employed multiplex
CR includes lower cost, greater time efficiency, and rou-
ine extension of the analysis to all 79 exons of the gene
including those whose deletions are extremely rare and are
ot usually assayed with multiplex PCR); it is also feasible in
enters that do not perform EMBs (Fig. 3 in Online
ppendix, Diagnostic work-up). For instance, MLPA did
Figure 4 In-Frame, Single Exon Deletion: Defective
Immunohistochemical Expression of Dystrophin
Endomyocardial biopsies of Patients #6 (A) and #13 (B), carriers of single
deletions of exon 48 (Table 1). The dystrophin immunostaining is defective in
both cases and shows different severity of loss of the immunostain.ot identify deletions of exons that were not tested by our fprior multiplex PCR, thus confirming that DYS deletions
ausing DCM cluster in the 5’ region (3,5–7,9) and mid-rod
omain exons (8,13,14) of the gene. In male patients who
o not undergo EMB, we will maintain the strategy of DYS
nalysis with MLPA as first-level screening. In the case of
egative results but evidence of X-linked inheritance in the
amily as well as either myopathy or increased sCPK in the
roband or relatives, we will perform second-level genetic
esting by direct sequencing of the coding and flanking
egions of the gene. Next-generation sequencing techniques
ill likely provide the possibility of low-cost, extensive
nalysis of the gene.
linical evolution. In our series, there were no sudden
ardiac deaths and syncope. Eight patients received the ICD
or marked LV dilation and dysfunction. Only 2 of 8
atients had a single run of NSVT on Holter monitoring at
aseline evaluation. None of the 8 patients had device
ntervention during a median follow-up of 14 months.
herefore, the arrhythmogenic risk seems to be much lower
han that observed in other types of inherited DCM, such as
ardiolaminopathies (26). By contrast, death for HF se-
erely influenced outcome, because more than one-half of
ur patients either died of HF or needed transplantation. As
hown by the cumulative incidence curve (Fig. 5A), the
ccurrence of both outcomes seemed fairly constant over the
rst 8 to 9 years of follow-up.
The prognostic factors for events were severe LV dilation
nd dysfunction and, paradoxically, the normal sCPK levels
nd absence of skeletal myopathy; this makes the diagnosis
articularly difficult but offers useful prognostic information.
he type of mutation does not correlate with the severity of
he phenotype and disease evolution; the outcome of the 3
atients with in-frame deletions of single exon 48 was
imilar to that of patients with more complex deletions,
oth in-frame and out-of-frame. The effect of single deletion
f exon 48 has been elegantly investigated in 5 male members
f a single family by Morrone et al. (27), who documented the
bnormal junction of exons 47 to 49 as well as the loss of exon
8 at the messenger ribonucleic acid level; of the 5 patients, 4
dults showed “sub-clinical DCM,” whereas an 8-year-old boy
ad normal echocardiogram.
The long-term prognosis after transplantation seems to be
xcellent, confirming prior observations in solitary case reports
r small series (28,29), with no impact of skeletal muscle
nvolvement on the outcome. Therefore, patients with
-linked DCM associated with DYS defects confirm as good
andidates for transplantation similar to other DCM patients.
linical advantages of a specific diagnosis. The correct
iagnosis of X-linked DCM associated with DYS defects
rovides the basis for disease-specific considerations, such as
he low arrhythmogenic risk and the high risk associated
ith end-stage HF. Treatments with statins and fibrates
hould be prevented before and after transplantation, be-
ause they might worsen the skeletal muscle status (30,31).
inally, genetic diagnosis allows extension of the testing inamilies, with identification of mutation carriers and healthy
n
r
p
u
a
D
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Dilated Cardiodystrophinopathies August 23, 2011:925–34female and younger male relatives, as well as the possibility
of pre-natal diagnosis.
Study limitations. The study is based on a relatively small
umber of patients; however, this in essence reflects the
arity of DYS-related DCM seen in routine cardiology
ractice; patients with DMD and BMD without DCM are
sually diagnosed for the myopathic clinical pattern (DMD
ppearing earlier than the cardiomyopathy), even though
Figure 5 Kaplan-Meier Event-Free Survival and Cum Inc for Com
(A) Kaplan-Meier event-free survival curve for the combined event of death and he
the figure immediately above the x-axis. (B) Cumulative incidence (Cum Inc) for th
interval [CI]) at the end of the follow-up is reported for each outcome.CM occurs in less than one-third of patients with BMD s(14,17). Lastly, the present study was designed to validate
the diagnostic work-up and to describe the long-term
evolution of the disease in probands; the monitoring and
follow-up of relatives are still ongoing.
Conclusions
Dilated cardiomyopathy associated with DYS defects
ng Events
nsplantation (HTx). The number of patients at risk is reported at the bottom of
eting events of death and HTx. Cumulative incidence (Cum Inc) (95% confidencepeti
art tra
e comphould be suspected in the presence of male probands,
933JACC Vol. 58, No. 9, 2011 Diegoli et al.
August 23, 2011:925–34 Dilated CardiodystrophinopathiesX-linked recessive inheritance, and increased sCPK. The
EMB documents the DYS defect, and genetic testing
concludes the diagnostic work-up. DYS-related DCM is
characterized by severe impairment of LV function,
marked LV dilation, and low arrhythmogenic risk; the
only factor that impacts survival seems to be end-
stage HF.
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Predictors of the Combined Endpoint of Death oTable 3 Predictors of the Combined Endpoin
n
Events
(% of Muta
Age at first diagnosis
37 yrs 17 7 (41%
37 yrs 17 10 (59%
Flu-like episode
No 26 11 (42%
Yes 8 6 (75%
sCPK
190 mU/ml 6 6 (100%
190 mU/ml 28 11 (40%
LVEF
28% 18 14 (78%
28% 16 3 (19%
LVEDD
70 mm 17 3 (18%
70 mm 17 14 (82%
RV diameter
25 28 14 (50%
25 6 3 (50%
TAPSE
19 22 13 (59%
19 12 4 (33%
ICD insertion
No 26 14 (54%
Yes 8 3 (37%
NYHA functional class
I 4 0
II 14 3 (21%
III 13 11 (85%
IV 3 3 (100%
NSVT
No 30 15 (50%
Yes 4 2 (50%
NYHA functional class III/IV
No 18 3 (17%
Yes 16 14 (87%
Type of mutation
In-frame deletions 21 10 (48%
Out-of-frame deletions 11 6 (54%
Point mutations 2 1 (50%
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